Paper37477752
Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
Ohyama R and 4 others. Clin Exp Nephrol, 2023. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study. Papers, record 37477752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37477752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Nephrotic Syndrome | Major topic |
| Child | |
| Humans | |
| Adolescent | |
| Rituximab | |
| Retrospective Studies | |
| Treatment Outcome | |
| Immunosuppressive Agents | |
| Recurrence | |
| Remission Induction |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2857421 | Long-term outcome for children with minimal-change nephrotic syndrome. | Lancet | 1985 | https://conductscience.org/library/papers/2857421 | PubMed |
| 2 | 35286456 | Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. | Pediatr Nephrol | 2022 | https://conductscience.org/library/papers/35286456 | PubMed |
| 3 | 32232637 | Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. | Pediatr Nephrol | 2020 | https://conductscience.org/library/papers/32232637 | PubMed |
| 4 | 31874801 | Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes. | Kidney Int | 2020 | https://conductscience.org/library/papers/31874801 | PubMed |
| 5 | 23739238 | Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. | Kidney Int | 2013 | https://conductscience.org/library/papers/23739238 | PubMed |
| 6 | 29913001 | Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. | JAMA Pediatr | 2018 | https://conductscience.org/library/papers/29913001 | PubMed |
| 7 | 35154548 | Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life. | Arch Med Sci | 2022 | https://conductscience.org/library/papers/35154548 | PubMed |
| 8 | 25085238 | Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. | Nephrol Dial Transplant | 2015 | https://conductscience.org/library/papers/25085238 | PubMed |
| 9 | 33786660 | Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country. | Pediatr Nephrol | 2021 | https://conductscience.org/library/papers/33786660 | PubMed |
| 10 | 30887110 | Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome. | Pediatr Nephrol | 2019 | https://conductscience.org/library/papers/30887110 | PubMed |
| 11 | 18465150 | Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. | Pediatr Nephrol | 2008 | https://conductscience.org/library/papers/18465150 | PubMed |
| 12 | 25277597 | Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. | Pediatr Nephrol | 2015 | https://conductscience.org/library/papers/25277597 | PubMed |
| 13 | 23271494 | Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. | Eur J Pediatr | 2013 | https://conductscience.org/library/papers/23271494 | PubMed |
| 14 | 36071552 | Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects. | Nephrol Dial Transplant | 2023 | https://conductscience.org/library/papers/36071552 | PubMed |
| 15 | 20049616 | Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. | Pediatr Nephrol | 2010 | https://conductscience.org/library/papers/20049616 | PubMed |
| 16 | 21394465 | Cyclophosphamide in steroid-dependent nephrotic syndrome. | Pediatr Nephrol | 2011 | https://conductscience.org/library/papers/21394465 | PubMed |
| 17 | 16126050 | Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. | J Pediatr | 2005 | https://conductscience.org/library/papers/16126050 | PubMed |
| 18 | 35354600 | Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. | J Am Soc Nephrol | 2022 | https://conductscience.org/library/papers/35354600 | PubMed |
| 19 | 27558467 | Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. | Clin Exp Nephrol | 2017 | https://conductscience.org/library/papers/27558467 | PubMed |
| 20 | 32337638 | Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. | Pediatr Nephrol | 2020 | https://conductscience.org/library/papers/32337638 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42435047 | Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/42435047 | PubMed |
| 42305001 | [Efficacy and safety of rituximab in children with refractory nephrotic syndrome]. | Zhongguo Dang Dai Er Ke Za Zhi | 2026 | https://conductscience.org/library/papers/42305001 | PubMed |
| 42014615 | When should sequential rituximab therapy for long-term B-cell depletion be initiated in children with steroid-sensitive nephrotic syndrome? | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/42014615 | PubMed |
| 41400699 | Optimal selection and timing of steroid-sparing therapy in childhood nephrotic syndrome: what determines long-term outcomes of adult survivors? | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/41400699 | PubMed |
| 41329290 | Comparison of efficacy of single-dose and double-dose rituximab in the treatment of refractory nephrotic syndrome in children: a retrospective study. | Pediatr Nephrol | 2026 | https://conductscience.org/library/papers/41329290 | PubMed |
| 41321785 | Identification of Risk Factors for Relapse following Rituximab Therapy in Children with Steroid-Sensitive Nephrotic Syndrome. | Kidney Dis (Basel) | 2025 | https://conductscience.org/library/papers/41321785 | PubMed |
| 39417849 | Response to Fujinaga - discontinuing immunosuppression in idiopathic nephrotic syndrome. | Pediatr Nephrol | 2025 | https://conductscience.org/library/papers/39417849 | PubMed |
| 38457032 | Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab. | Clin Exp Nephrol | 2024 | https://conductscience.org/library/papers/38457032 | PubMed |
| 38456917 | Pre-emptive rituximab administration for discontinuation of steroid-sparing agents in patients with complicated frequently-relapsing or steroid-dependent nephrotic syndrome. | Pediatr Nephrol | 2024 | https://conductscience.org/library/papers/38456917 | PubMed |
| 38010466 | Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial). | Clin Exp Nephrol | 2024 | https://conductscience.org/library/papers/38010466 | PubMed |
| 37864679 | Changes in adverse events after multiple rituximab courses in patients with complicated steroid-dependent nephrotic syndrome. | Clin Exp Nephrol | 2024 | https://conductscience.org/library/papers/37864679 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37477752
GET https://conductscience.org/api/papers/v1/37477752/references?page=2